# Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy

> **NCT00175903** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 1701 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Levetiracetam
- **DRUG:** Carbamazepine Controlled Release (CBZ-CR)
- **DRUG:** Valproate Extended Release

## Key facts

- **NCT ID:** NCT00175903
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 1701 (ACTUAL)
- **Last updated:** 2015-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00175903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00175903, "Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT00175903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*